Ascletis Pharma’s ASC22 Combo Therapy Shows Promise in HIV Functional Cure Clinical Trial
China-based Ascletis Pharma Inc., (HKG: 1672) has announced that the Shanghai Public Health Clinical Center...
Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group Get NMPA Approval for Solid Tumor Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
Taiwan’s TFDA Orders Recall of Two Nucala Batches Due to Glass Fragments
The Food and Drug Administration (FDA) bureau of Taiwan, part of Greater China, has issued...
Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review
US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...
Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with...
Vcanbio’s VUM02 Stem Cell Therapy Accepted for Review by China’s CDE for aGvHD Treatment
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the Center...
NMPA Updates List of Medical Devices Exempt from Clinical Evaluation in China
The National Medical Products Administration (NMPA) has released an updated version of the “List of...
Chinese Health Authorities Unveil Key Reform Tasks for Medical System in H2 2023
The National Health Commission (NHC), National Development and Reform Commission (NDRC), Ministry of Finance (MoF),...
NHSA Releases Official Guidelines for Drug Negotiations and Bidding for NRDL Update
The National Healthcare Security Administration (NHSA) has officially released the “Negotiation Drug Renewals” and “Non-exclusive...
Carbon Medical Technology Secures Over RMB 100 Million in Series A Financing for Interventional Therapy
Shenzhen-based Carbon Medical Technology Co., Ltd has reportedly raised over RMB 100 million (USD 13.9...
BeiGene’s Tislelizumab Receives Positive CHMP Opinion for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received a...
CanSino Biologics Granted Approval by Health Canada for Zoster Vaccine Candidate CS-2032
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced receiving approval from Health Canada...
Bavarian Nordic’s RSV Vaccine Candidate Fails Phase III Trial, Discontinues Program
Denmark-based Bavarian Nordic A/S (CPH: BAVA) has revealed that its pipeline respiratory syncytial virus (RSV)...
National Health Commission Launches One-Year Anti-Corruption Campaign in Pharmaceutical Sector
The emergency response department of the National Health Commission (NHC) has released a notification signaling...
FDA Assures No Disruption to US Drug Supply Chain After Pfizer Warehouse Tornado
The US Food and Drug Administration (FDA) has issued a statement this week, ruling out...
Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies
China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...
Antengene Corp. Receives FDA Fast-Track Designation for Xpovio in Myelofibrosis Treatment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving fast-track designation from the US...
Riparian Pharmaceuticals Secures Exclusive License Agreement with Pfizer for Cardiovascular Program
US-based Riparian Pharmaceuticals, Inc., a biotechnology company focused on cardiovascular diseases and co-incubated by Viva...
Acotec Scientific and Boston Scientific Announce Comprehensive Collaboration Agreement
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a cooperation framework and service framework...
Hansoh Pharmaceutical’s Ibrexafungerp NDA Accepted for Review by China’s NMPA for VVC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that the National Medical Products...